TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Recruiting · NCT06533826 · Registry updated 2026-08-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-08-26 | NCT06533826 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ana C Garrido-Castro, MD | 2 |
| AstraZeneca | 806 |
| Translational Breast Cancer Research Consortium | 19 |
11 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Baylor College of Medicine | Houston | United States | 306 |
| Beth Israel Deaconess Medical Center | Boston | United States | 462 |
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Georgetown University Medical Center | Washington D.C. | United States | 62 |
| Montefiore Einstein Comprehensive Cancer Center | The Bronx | United States | 9 |
| University of Alabama | Birmingham | United States | 29 |
| University of Chicago Medical Center | Chicago | United States | 152 |
| University of North Carolina | Chapel Hill | United States | 101 |
| University of San Francisco | San Francisco | United States | 3 |
| Vanderbilt Cancer Center | Nashville | United States | 2 |
| Yale University Cancer Center | New Haven | United States | 6 |